Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T20:41:39.612Z.
Calculation as of: 2026-10-06T20:41:39.612Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 786381cf23009ce26769892c1927912581314c354aa2592277191dd3add0e379
PE RATIO
N/A
PE RATIO AVG TTM
N/A
PE RATIO AVG 3Y
N/A
PE RATIO AVG 5Y
N/A
PE RATIO AVG 10Y
N/A
PE RATIO AVG 15Y
N/A
PE RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GridAI Technologies Corp. (GRDX) | $29.74M | N/A | N/A | N/A | N/A |
| Context Therapeutics Inc. (CNTX)vs › | $29.57M | N/A | N/A | N/A | N/A |
| MIRA Pharmaceuticals, Inc. (MIRA)vs › | $29.91M | N/A | N/A | N/A | N/A |
| Quantum Cyber N.V. (QUCY)vs › | $29.37M | N/A | N/A | N/A | N/A |
| Rockwell Medical, Inc. (RMTI)vs › | $30.19M | N/A | 344.49 | 512.54 | 512.54 |
| SCYNEXIS, Inc. (SCYX)vs › | $30.44M | N/A | 1.92 | 1.92 | 1.92 |
| MDxHealth S.A. (MDXH)vs › | $30.81M | N/A | N/A | N/A | N/A |
| CervoMed Inc. (CRVO)vs › | $30.92M | N/A | 876.90 | 876.90 | 876.90 |
| BeyondSpring Inc. (BYSI)vs › | $28.47M | N/A | N/A | N/A | N/A |
| Accuray Incorporated (ARAY)vs › | $31.11M | N/A | 241.49 | 241.49 | 115.68 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$4.17
Forward EPS (Est.)
$-5.22
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PE RATIO |
|---|---|
| 2023-11-13 | 0.33 |
| 2023-11-10 | 0.33 |
| 2023-11-09 | 0.34 |
| 2023-11-08 | 0.35 |
| 2023-11-07 | 0.34 |
| 2023-11-06 | 0.35 |
| 2023-11-03 | 0.38 |
| 2023-11-02 | 0.37 |
| 2023-11-01 | 0.34 |
| 2023-10-31 | 0.35 |
| 2023-10-30 | 0.34 |
| 2023-10-27 | 0.33 |
| 2023-10-26 | 0.35 |
| 2023-10-25 | 0.35 |
| 2023-10-24 | 0.36 |
| 2023-10-23 | 0.35 |
| 2023-10-20 | 0.35 |
| 2023-10-19 | 0.36 |
| 2023-10-18 | 0.37 |
| 2023-10-17 | 0.40 |
| 2023-10-16 | 0.42 |
| 2023-10-13 | 0.42 |
| 2023-10-12 | 0.45 |
| 2023-10-11 | 0.38 |
| 2023-10-10 | 0.37 |
| 2023-10-09 | 0.37 |
| 2023-10-06 | 0.39 |
| 2023-10-05 | 0.36 |
| 2023-10-04 | 0.36 |
| 2023-10-03 | 0.36 |
| 2023-10-02 | 0.35 |
| 2023-09-29 | 0.35 |
| 2023-09-28 | 0.36 |
| 2023-09-27 | 0.36 |
| 2023-09-26 | 0.37 |
| 2023-09-25 | 0.39 |
| 2023-09-22 | 0.42 |
| 2023-09-21 | 0.43 |
| 2023-09-20 | 0.42 |
| 2023-09-19 | 0.43 |
| 2023-09-18 | 0.47 |
| 2023-09-15 | 0.53 |
| 2023-09-14 | 0.61 |
| 2023-09-13 | 0.52 |
| 2023-09-12 | 0.48 |
| 2023-09-11 | 0.48 |
| 2023-09-08 | 0.50 |
| 2023-09-07 | 0.55 |
| 2023-09-06 | 0.51 |
| 2023-09-05 | 0.54 |
| 2023-09-01 | 0.35 |
| 2023-08-31 | 0.37 |
| 2023-08-30 | 0.36 |
| 2023-08-29 | 0.37 |
| 2023-08-28 | 0.39 |
| 2023-08-25 | 0.39 |
| 2023-08-24 | 0.40 |
| 2023-08-23 | 0.41 |
| 2023-08-22 | 0.42 |
| 2023-08-21 | 0.42 |
| 2023-08-18 | 0.44 |
| 2023-08-17 | 0.48 |
| 2023-08-16 | 0.48 |
| 2023-08-15 | 0.51 |
